#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating patients with obesity or diabetes who are prescribed GLP-1 receptor agonists should be aware that these medications may reduce the risk of developing cannabis and alcohol use disorders, potentially offering an additional therapeutic benefit beyond glycemic control or weight management. This finding could influence treatment selection discussions with patients at higher baseline risk for substance use disorders, as GLP-1 agonists may provide dual benefits of metabolic improvement and reduced addictive substance use. Patients currently struggling with cannabis use may benefit from discussing GLP-1 agonist eligibility with their clinicians if they have concurrent metabolic conditions, as the medication could address both conditions simultaneously.
# Clinical Summary Recent evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications primarily used for type 2 diabetes and weight management, are associated with reduced incidence of substance use disorders including cannabis use. This finding emerges from observational or epidemiological data examining substance use outcomes in patients treated with GLP-1 RAs compared to those receiving alternative therapies. The mechanism underlying this protective association remains unclear but may involve effects on reward pathways, appetite regulation, or behavioral reinforcement systems that overlap with addiction neurobiology. For clinicians, this suggests that GLP-1 RAs may offer an additional benefit beyond glucose control or weight reduction, particularly in patients with comorbid metabolic conditions and substance use risk factors or history. However, these medications should not be considered a primary treatment for cannabis use disorder, and patients requiring cannabis cessation should continue to receive evidence-based addiction counseling and behavioral interventions. Clinicians managing patients with diabetes or obesity who have concurrent substance use concerns may consider GLP-1 RAs as part of a comprehensive treatment approach, though further mechanistic research is needed to establish causality and identify which patient populations benefit most.
“What we’re seeing with GLP-1 agonists suggests that addressing the underlying dysregulation of reward pathways and impulse control may be more clinically relevant than we’ve previously emphasized, which means some of my patients struggling with cannabis dependence might benefit from a metabolic intervention rather than another behavioral program alone.”
💊 Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with reduced risk of developing substance use disorders, including cannabis use, though the mechanistic basis for this association remains unclear and could reflect weight loss effects, improved metabolic health, or direct neurobiological pathways affecting reward processing. While these findings are intriguing for patients with comorbid obesity and diabetes, clinicians should interpret them cautiously given potential confounding by socioeconomic factors, healthcare engagement patterns, and selection bias in who receives GLP-1 therapy, as well as the challenge of distinguishing association from causation in observational studies. The preliminary nature of this evidence means GLP-1 RAs should not currently be prescribed specifically for SUD prevention, and any perceived protective effect should not delay evidence-based addiction treatment or behavioral interventions in patients with active substance use. Nevertheless,
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: